Cargando…

The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response

Ataxia telangiectasia and Rad-3 related kinase (ATR) signals DNA lesions and replication stress (RS) to the S and G2/M checkpoints and DNA repair pathways making it a promising target to exploit the dysregulated DNA damage response in cancer. ATR inhibitors (ATRi) are under clinical investigation as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bradbury, Alice, Zenke, Frank T., Curtin, Nicola J., Drew, Yvette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367423/ https://www.ncbi.nlm.nih.gov/pubmed/35954206 http://dx.doi.org/10.3390/cells11152361

Ejemplares similares

Targeting the ATR-CHK1 Axis in Cancer Therapy
por: Rundle, Stuart, et al.
Publicado: (2017)

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting
por: Bradbury, Alice, et al.
Publicado: (2020)

Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer
por: Sharma Saha, Sweta, et al.
Publicado: (2021)

ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer
por: Feng, Wenlong, et al.
Publicado: (2020)

ATR Inhibitors in Platinum-Resistant Ovarian Cancer
por: Li, Siyu, et al.
Publicado: (2022)

The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation
por: Middleton, Fiona K., et al.
Publicado: (2018)

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2021)

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
por: Peasland, A, et al.
Publicado: (2011)

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms
por: Southgate, Harriet E. D., et al.
Publicado: (2020)

The development of PARP inhibitors in ovarian cancer: from bench to bedside
por: Drew, Yvette
Publicado: (2015)

Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells
por: King, David, et al.
Publicado: (2021)

Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors
por: Turchick, Audrey, et al.
Publicado: (2023)

Aldehyde dehydrogenase inhibitors promote DNA damage in ovarian cancer and synergize with ATM/ATR inhibitors
por: Grimley, Edward, et al.
Publicado: (2021)

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor
por: Franklin, Miriam, et al.
Publicado: (2018)

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling
por: Smith, Hannah L., et al.
Publicado: (2022)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models
por: Xu, Haineng, et al.
Publicado: (2021)

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
por: Drew, Yvette, et al.
Publicado: (2016)

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
por: Drew, Yvette, et al.
Publicado: (2016)

Prospects for the Use of ATR Inhibitors to Treat Cancer
por: Wagner, Jill M., et al.
Publicado: (2010)

Emerging strategies for cancer therapy by ATR inhibitors
por: Yano, Kimiyoshi, et al.
Publicado: (2023)

Mutation analysis of the ATR gene in breast and ovarian cancer families
por: Heikkinen, Katri, et al.
Publicado: (2005)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition
por: Middleton, Fiona K., et al.
Publicado: (2015)

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
por: Hur, Jin, et al.
Publicado: (2021)

Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer
por: Leszczynska, Katarzyna B., et al.
Publicado: (2016)

Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2019)

Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents
por: Jo, Ukhyun, et al.
Publicado: (2021)

The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy
por: Vendetti, Frank P., et al.
Publicado: (2023)

SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
por: Llorca-Cardenosa, Marta J., et al.
Publicado: (2022)

Efficacy of ATR inhibitors as single agents in Ewing sarcoma
por: Nieto-Soler, Maria, et al.
Publicado: (2016)

Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA
por: Menolfi, Demis, et al.
Publicado: (2018)

ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer
por: Schultz, Christopher W, et al.
Publicado: (2023)

Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors
por: Golder, Anya, et al.
Publicado: (2022)

ATR activation is regulated by dimerization of ATR activating proteins
por: Thada, Vaughn, et al.
Publicado: (2021)

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
por: Hall, Amy B., et al.
Publicado: (2014)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

ATR-IR Investigation of Solvent Interactions with Surface-Bound Polymers
por: Mathis, Christian H., et al.
Publicado: (2016)

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer
por: Kundu, Kiran, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cssm25n0i4ru85tc3u8h2ic2dp